Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
Collaborating closely with data curators, multi-omics data scientists and AI engineers to integrate and enrich disease datasets, and test and validate models Applying hybrid modelling approaches to limited data
-
vitro assays of immune function are essential. The current project, which is funded via the MSD/Crick Research Alliance, aims to elucidate the biology responsible for a genetic association with
-
for the game changing impact of our science globally. Our employees enjoy access to state-of-the-art technology and a diverse range of specialist training opportunities, including support for leadership and
-
at all levels; offer vital services to scientists in the public and private sectors within the member states; develop new instruments and methods; and engage actively in technology transfer
-
functional dimensions of human long non-coding RNAs (lncRNAs) in regulating human cardiovascular development, metabolism, function and disease. These new lncRNA functions include the broad interactions
-
cancer patients. The lab employs cutting-edge technologies (immunopeptidomics, T cell engineering, single-cell transcriptomics, spatial transcriptomics, CRISPR technologies) paired with in vivo animal
-
CDE base. It also houses 1 national key laboratory, 1 national clinical research center of the Ministry of Science & Technology, 1 basic science center of the National Natural Science Foundation
-
join our team in developing innovative CAR-T cell therapies for colorectal cancer. Our lab focuses on engineering immune cells with greater precision, persistence, and safety, using synthetic biology
-
together the brightest minds who have completed a PhD in the natural sciences or engineering and who aim to pursue a research project that includes the application of artificial intelligence (AI
-
Nature Careers | Northern British Columbia Fort Nelson, British Columbia | Canada | about 1 month ago
. Potential projects focus on severe ADRs to a range of different medications. Current priority ADRs include cisplatin-induced ototoxicity, anthracycline-induced cardiotoxicity, COVID-19 vaccine-induced